Intussusception after monovalent rotavirus vaccine-United States, Vaccine Adverse Event Reporting System (VAERS), 2008-2014
- PMID: 26276687
- DOI: 10.1016/j.vaccine.2015.07.054
Intussusception after monovalent rotavirus vaccine-United States, Vaccine Adverse Event Reporting System (VAERS), 2008-2014
Abstract
Background: In 2006 and 2008, two new rotavirus vaccines (RotaTeq [RV5] and Rotarix [RV1]) were introduced in the United States. US data on intussusception have been mostly related to RV5, with limited data on RV1.
Methods: We assessed intussusception events following RV1 reported to the Vaccine Adverse Event Reporting System (VAERS), a US national passive surveillance system, during February 2008-December 2014. We conducted a self-controlled risk interval analysis using Poisson regression to estimate the daily reporting ratio (DRR) of intussusception after the first 2 doses of RV1 comparing average daily reports 3-6 versus 0-2 days after vaccination. We calculated the excess risk of intussusception per 100,000 vaccinations based on DRRs and background rates of intussusception. Sensitivity analyses were conducted to assess effects of differential reporting completeness and inaccuracy of baseline rates.
Results: VAERS received 108 confirmed insusceptible reports after RV1. A significant clustering was observed on days 3-8 after does1 (p=0.001) and days 2-7 after dose 2 (p=0.001). The DRR comparing the 3-6 day and the 0-2 day periods after RV1 dose 1 was 7.5 (95% CI=2.3, 24.6), translating to an excess risk of 1.6 (95% CI=0.3, 5.8) per 100,000 vaccinations. The DRR was elevated but not significant after dose 2 (2.4 [95% CI=0.8,7.5]). The excess risk ranged from 1.2 to 2.8 per 100,000 in sensitivity analysis.
Conclusions: We observed a significant increased risk of intussusception 3-6 days after dose 1 of RV1. The estimated small number of intussusception cases attributable to RV1 is outweighed by the benefits of rotavirus vaccination.
Keywords: Intussusception; Rotarix vaccines; Safety monitoring; Vaccine adverse event.
Published by Elsevier Ltd.
Similar articles
-
Safety profile of rotavirus vaccines among individuals aged ≥8 months of age, United States, vaccine adverse event reporting system (VAERS), 2006-2019.Vaccine. 2021 Jan 22;39(4):746-750. doi: 10.1016/j.vaccine.2020.11.026. Epub 2020 Nov 29. Vaccine. 2021. PMID: 33267969
-
Intussusception following rotavirus vaccination: an updated review of the available evidence.Expert Rev Vaccines. 2014 Nov;13(11):1339-48. doi: 10.1586/14760584.2014.942223. Epub 2014 Jul 26. Expert Rev Vaccines. 2014. PMID: 25066368 Review.
-
Intussusception risk after rotavirus vaccination in U.S. infants.N Engl J Med. 2014 Feb 6;370(6):503-12. doi: 10.1056/NEJMoa1303164. Epub 2014 Jan 14. N Engl J Med. 2014. PMID: 24422676
-
Intussusception after rotavirus vaccines reported to US VAERS, 2006-2012.Pediatrics. 2013 Jun;131(6):1042-9. doi: 10.1542/peds.2012-2554. Epub 2013 May 13. Pediatrics. 2013. PMID: 23669521
-
Vaccines for preventing rotavirus diarrhoea: vaccines in use.Cochrane Database Syst Rev. 2012 Nov 14;11:CD008521. doi: 10.1002/14651858.CD008521.pub3. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2019 Mar 25;3:CD008521. doi: 10.1002/14651858.CD008521.pub4. PMID: 23152260 Updated. Review.
Cited by
-
Fourteen years' clinical experience and the first million babies protected with human live-attenuated vaccine against rotavirus disease in Italy.Hum Vaccin Immunother. 2021 Nov 2;17(11):4636-4645. doi: 10.1080/21645515.2021.1955611. Epub 2021 Aug 9. Hum Vaccin Immunother. 2021. PMID: 34370615 Free PMC article.
-
Product review of the rotavirus vaccines ROTASIIL, ROTAVAC, and Rotavin-M1.Hum Vaccin Immunother. 2021 Apr 3;17(4):1223-1234. doi: 10.1080/21645515.2020.1804245. Epub 2020 Oct 29. Hum Vaccin Immunother. 2021. PMID: 33121329 Free PMC article. Review.
-
Adverse Events and Healthcare Utilization Associated With Outpatient Parenteral Antimicrobial Therapy Among Older Versus Younger Adults.Open Forum Infect Dis. 2020 Aug 26;7(10):ofaa358. doi: 10.1093/ofid/ofaa358. eCollection 2020 Oct. Open Forum Infect Dis. 2020. PMID: 33094112 Free PMC article.
-
Evaluation of the safety profile of rotavirus vaccines: a pharmacovigilance analysis on American and European data.Sci Rep. 2020 Aug 12;10(1):13601. doi: 10.1038/s41598-020-70653-3. Sci Rep. 2020. PMID: 32788620 Free PMC article.
-
Analysis of health outcomes in vaccinated and unvaccinated children: Developmental delays, asthma, ear infections and gastrointestinal disorders.SAGE Open Med. 2020 May 27;8:2050312120925344. doi: 10.1177/2050312120925344. eCollection 2020. SAGE Open Med. 2020. PMID: 32537156 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources